Somewhat Positive Press Coverage Somewhat Unlikely to Affect Oxford Immunotec Global PLC (OXFD) Stock Price
News headlines about Oxford Immunotec Global PLC (NASDAQ:OXFD) have trended somewhat positive on Saturday, Accern reports. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Oxford Immunotec Global PLC earned a news impact score of 0.12 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.1284783694227 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the headlines that may have effected Accern’s scoring:
- Huhtamäki Oyj announces final tender offer results for its outstanding notes maturing in 2020 (pr-inside.com)
- Oxford Immunotec Announces Update in Patent Infringement Litigation (4-traders.com)
- Oxford Immunotec Global PLC (OXFD) Receives Buy Rating from Cowen and Company (americanbankingnews.com)
- Oxford Immunotec Global PLC (OXFD) Coverage Initiated by Analysts at BTIG Research (americanbankingnews.com)
- Advice by Analysts to Buy Healthcare Stock: Oxford Immunotec Global PLC (OXFD) – Street Observer (press release) (streetobserver.com)
Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) traded down 2.61% during midday trading on Friday, reaching $16.80. The company’s stock had a trading volume of 149,331 shares. The stock’s 50 day moving average is $16.10 and its 200 day moving average is $15.51. Oxford Immunotec Global PLC has a 12 month low of $11.71 and a 12 month high of $19.51. The stock’s market capitalization is $387.68 million.
Oxford Immunotec Global PLC (NASDAQ:OXFD) last announced its earnings results on Tuesday, August 1st. The company reported ($0.32) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.32). The firm had revenue of $26.10 million for the quarter, compared to analysts’ expectations of $25.05 million. Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. The firm’s quarterly revenue was up 35.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.29) earnings per share. On average, analysts forecast that Oxford Immunotec Global PLC will post ($1.63) EPS for the current fiscal year.
A number of equities analysts have recently issued reports on the company. Cowen and Company reissued a “buy” rating and set a $19.00 target price on shares of Oxford Immunotec Global PLC in a research note on Thursday. BTIG Research assumed coverage on Oxford Immunotec Global PLC in a research note on Thursday. They set a “buy” rating and a $21.00 target price for the company. Zacks Investment Research downgraded Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Wednesday, August 30th. Piper Jaffray Companies reissued a “buy” rating and set a $26.00 target price on shares of Oxford Immunotec Global PLC in a research note on Thursday, August 3rd. Finally, ValuEngine upgraded Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. Oxford Immunotec Global PLC currently has a consensus rating of “Hold” and a consensus target price of $20.75.
ILLEGAL ACTIVITY NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-oxford-immunotec-global-plc-oxfd-stock-price/1599542.html.
In other Oxford Immunotec Global PLC news, Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $15.82, for a total value of $47,460.00. Following the transaction, the director now owns 18,000 shares of the company’s stock, valued at $284,760. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Peter Edwardson sold 22,371 shares of the company’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $17.70, for a total value of $395,966.70. Following the completion of the transaction, the chief operating officer now directly owns 102,644 shares in the company, valued at approximately $1,816,798.80. The disclosure for this sale can be found here. Insiders sold 95,110 shares of company stock worth $1,578,027 in the last ninety days. 7.58% of the stock is owned by corporate insiders.
About Oxford Immunotec Global PLC
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.